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Material and Methods
Identification of Bora
To identify the molecular trigger for the G2-M transition, we set up a targeted siRNA screen for the function of novel G2-induced genes by quantitatively measuring the kinetics of mitotic entry. Whitfield et al. (S1) have systematically analyzed the gene transcriptional profile across the cell cycle and identified 239 genes in the human transcriptome that are induced in G2, of which twenty-two genes with strong G2-induction are functionally uncharacterized. These novel genes include FLJ10156, FLJ90328, FLJ11029, FLJ22624, FLJ40629, FLJ11252, FLJ20354, FLJ14502, FLJ13154, FLJ20333, DKFZp434C245, LOC283431, C9orf140, C20orf129, p37NB, HAN11, DDA3, ARL6IP, ARL6IP2, ANP32E, UBE2S and ARHGAP11A, among which the first seven genes have the best induction profiles in G2. SMARTpool siRNAs (Dharmacon, Inc.) against these seven genes were purchased from Dharmacon, Inc. and transfected into HeLa cells using DharmaFect 1 (Dharmacon, Inc.). Transfected HeLa cells were synchronized at the G1-S boundary by a double-thymidine arrest. Upon release from the second thymidine arrest, the kinetics of the mitotic entry was analyzed by FACS using a propidium iodine staining and an anti-MPM2 antibody staining. The anti-MPM2 antibody recognizes phospho-proteins in mitotic cells and was used here to determine the mitotic index. This study led to the identification of FLJ22624 as a gene regulating mitotic entry. A Drosophila homolog of FLJ22624, dBora, was previously reported as a regulator for asymmetric cell division (S2) .
The Drosophila and human Bora share limited sequence identity in a 164-aa region (31% aa identity between aa12-175 of human Bora).
Plasmids and recombinant proteins and antibodies
Human Bora cDNA from clone BC056876 (Open Biosystems) was sub-cloned into the pCS2-FA and pCS2-eGFP-FA vectors. MBP-tagged full-length Bora and His-tagged Bora-N (1-312aa) and Bora-C (355-559aa) were expressed in E. coli and purified (Fig. S5B ). Inactive recombinant GST-Plk1, His-Plx1, His-Plx1-N172A (kinase-dead) (S3), His-Plx1-W408F (S4) and His-Plx1-T201D were expressed in asynchronous Sf9 cells for 48 hours and purified with Talon beads (BD Bioscience) (Fig. S5B ). Active recombinant Plx1 was expressed in Sf9 cells for 44 hours and then treated with 250 nM okadaic acid for 4 h prior to harvesting (S5) . GST-Plk1-K (aa 13-345), GST-PBD (aa 352-603 of Plk1) and His-Aur-A were expressed in E. coli and purified.
Antisera against His-tagged Bora fragments (aa1-312 and aa355-559) and against the GFP protein were generated in rabbits and affinity-purified against respective antigens. Affinitypurified anti-Plx1 and anti-Mad2 antibodies were described previously (S6, S7) . The following antibodies were from commercial sources: anti-MPM2, anti-Aur-A-T288-P, and anti-Cdk1-Y15-P antibodies (Cell Signaling), anti-Plk1-T210-P antibody (BD Biosciences), anti-cyclin B1, antiPlk1, anti-Wee1, anti-Aur-A, anti-myc, anti-Hsp70, and anti-p38MAPK antibodies (Santa Cruz Biotechnology).
Proteomics a) Purification of the Bora complex
To analyze the biochemical basis of Bora function, we established HeLa S3 cell lines stably expressing the GFP-and S-tagged Bora below the endogenous Bora level. Tagged Bora complex was first purified by an anti-GFP antibody column (S8) from G2 cells that were harvested 9 hours post-thymidine arrest. The Bora complex was cleaved from the column by the Tev protease on a site engineered between the GFP and S tags, further purified with a S-protein column, eluted in urea, and proteolytically digested with trypsin (S9).
b) LC-MS/MS
A 100-μm i.d. capillary with a 5-μm pulled tip was packed with 10 cm of 5-μm Aqua C18 material (Phenomenex). The column was then equilibrated for 30 minutes with Buffer A (5% acetonitrile/0.1% formic acid) and the protein digest was pressure-loaded onto it. The column was placed inline with an Agilent 1100 quaternary HPLC and analyzed by using an onestep separation which consisted of a 120-min gradient from 0% to 100% Buffer B (80% acetonitrile/0.1% formic acid). As peptides eluted from the microcapillary column, they were electrosprayed directly onto an LTQ mass spectrometer (ThermoFinnigan) with the application of a distal 2.4-kV spray voltage. A cycle of one full-scan mass spectrum (400-1,400 m/z) was followed by three data-dependent tandem MS spectra at a 35% normalized collision energy.
Application of MS scan functions and HPLC solvent gradients were controlled by the XCalibur datasystem.
c) Analysis of tandem MS
Tandem MS spectra were analyzed by using the following software analysis protocol.
Poor-quality spectra were removed from the data set by using an automated spectral quality assessment algorithm (S10). Tandem MS spectra remaining after filtering were searched with the SEQUEST algorithm (S11) against a Human Database concatenated to a decoy database in which the sequence for each entry in the original database was reversed (S12) . No enzyme specificity was considered for any search. SEQUEST results were assembled and filtered by using the DTASelect (version 2.0) program (S13). DTASelect 2.0 uses a linear discriminant analysis to dynamically set XCorr and DeltaCN thresholds for the entire data set to achieve a user-specified false positive rate (5% in this analysis). The false positive rates are estimated by the program from the number and quality of spectral matches to the decoy database. Plk1 was identified as a Bora-associated protein in this analysis. A total of 28 Plk1 peptides, covering 31.8% of the Plk1 sequence, were identified and the spectra for 10 Plk1 peptides had the XCorr score greater than 4.5 and the DeltaCN value greater than 0.25. No Aur-A peptide was identified.
Cell culture and transfection
HeLa S3 and HeLa cells were cultured in Dulbecco's Modified Eagles Medium containing 10% fetal bovine serum (Invitrogen) and antibiotics. To analyze cell cycle progression, cells were synchronized at the G1-S boundary by a double-thymidine treatment (TT; a 18-hr thymidine arrest and a 9-hr release, followed by a 18-hr thymidine arrest) and then released (S14). Alternatively, cells were synchronized at prometaphase by a thymidinenocodazole arrest (TN; a 18-hr thymidine arrest and a 5-hr release, followed by a 14-hr nocodazole arrest) (S7, S14) . Mitotic cells were then collected by shake-off.
Two independent OnTargetPlus siRNAs (Dharmacon Inc.) for human Bora efficiently depleted endogenous Bora and both generated a delay in mitotic entry, confirming the specificity of the phenotype. The siRNAs against Bora are (A) 5'-CTATGAGACTTCAGATGTA-3' and (B) 5'-TAACTAGTCCTTCGCCTAT-3'. siRNAs against Plk1 (S15) and Aur-A are 5'-AGATTGTGCCTAAGTCTCT-3' and 5'-GAACTTACTTCTTGGATCA-3', respectively. The control siRNA (siGL2) is 5'-CGTACGCGGAATACTTCGATT-3'. To determine the kinetics of mitotic entry in Bora, 4, S1, S2 and S6) , siRNAs were transfected during the second thymidine arrest. Phenotypes observed in Plk1 and Aur-A-depleted cells were independently confirmed by treatment of G2 cells with their respective inhibitors, BI 2536 and VX-680 (S16, S17) (data not shown).
DNA transfection was performed using Lipofectamine 2000 (Invitrogen). HeLa cells expressing GFP-Bora or myc-Aur-A were analyzed at 38 hours post-transfection by Western blotting and by FACS (Figs. 4 & S3) . 293 cells expressing myc-Plk1 or myc-Plk1-K were harvested at 48 hours post-transfection and the kinase activities were analyzed on anti-myc immunoprecipitates using casein as a substrate (Fig. 3, B 
and G).
A Bora variant gene (rBora) resistant to siBora-A was constructed by silent mutations in the coding sequence (Fig. S1 ). GFP-rBora and control GFP were subcloned into the pBabe vector and subsequently transfected into Phoenix-Ampho packaging cells. The viral supernatants were used to infect HeLa cells and stable clones were isolated and characterized after selection for 2 weeks with 0.4 µg/ml puromycin.
Immunoprecipitation
Antibodies against Bora, Plk1 or control IgG were coupled to Affi-Prep Protein A beads (Bio-Rad) at a concentration of 0.3 mg/ml. HeLa or HeLa S3 cell pellets were lyzed in the NP-40 lysis buffer (50 mM Tris-HCl pH 8.0, 140 mM NaCl, 1% NP-40, 10% glycerol, 0.1 mM EDTA, 1 mM DTT, 10 µg/ml each of leupepin, pepstatin and chymostatin). Lysates were centrifuged and incubated with Protein A beads coupled with pre-immune rabbit IgG at 4°C for 1 h. The precleared lysates were then incubated with anti-Bora, Plk1 or control IgG antibodies/Protein A beads at 4°C overnight. Beads were recovered by centrifugation, washed five times with XB buffer (10 mM HEPES-KOH, pH7.8, 100 mM KCl, 1 mM MgCl 2 , 0.1 mM CaCl 2 , 50 mM sucrose) containing 500 mM KCl and 0.5% NP-40, and twice with XB. The immunoprecipitates were analyzed by Western blotting with appropriate antibodies (Figs. 1B and S4, B-C). The Plk1 immunoprecipitates were also assayed for its kinase activity using casein as a substrate (Figs. 1B
& 2E).
Kinase assays
To analyze Aur-A-mediated phosphorylation of Plx1, Plx1-N172A, and Plx1-T201D phosphorylated. To dephosphorylate active Plx1 (Fig. 3D) , 5 μg Plx1 were incubated with 400 unit λPPase in the presence of 2 mM MnCl 2 in 10 μl for 60 min at room temperature. The reaction was stopped by addition of EGTA and dephosphorylated Plx1 underwent the Bora-and Aur-A-mediated activation, as described above. Similarly, recombinant Plx1-T201D was dephosphorylated by λPPase prior to its incubation with Bora and Aur-A (Fig. 3E ).
To assay the activation of Plk1 and Plk1-K by Aur-A and Bora ( Fig. 3B & 3G) , myc-Plk1 and myc-Plk1-K were expressed in 293 cells by transient transfection in 15-cm dishes. Cells were harvested at 48 hours post-transfection and lyzed in the NP-40 lysis buffer. Myc-Plk1 and myc-Plk1-K were purified by the anti-myc antibody/Protein A beads. Purified myc-Plk1 and myc-Plk1-K on beads were then incubated with λPPase at room temperature for 90 minutes.
Upon termination of the dephosphorylation reactions by EGTA, myc-Plk1 and myc-Plk1-K beads were incubated with or without 300 nM Aur-A and 700 nM MBP-Bora/MBP in the presence of unlabeled ATP in 10 µl KRB for 30 min at room temperature. After extensive wash to remove Aur-A, myc-Plk1 and myc-Plk1-K beads were analyzed by Western blotting for Plk1-T210-P or assayed for the Plk1 activity, as described above for Plx1.
In vitro binding assays
Bora Figure S7 . (S16, S17, S24) . HeLa S3 cells were incubated with 2 mM thymidine for 18 hours, released for 5 hours and incubated with 100 ng/ml nocodazole (noc) for 12 hours. Subsequently, prometaphase cells were incubated for one hour with 100 ng/ml nocodazole plus 5 μM MG132 and then for another hour with nocodazole and MG132 plus one of the following drugs: DMSO, 25 μM Purvalanol A, 1 μM VX-680 and 300 nM BI 2536. Prometaphase cells were then harvested by mitotic shake-off (A). MG132 is a proteasome inhibitor, the presence of which in nocodazole-arrested prometaphase cells prevents mitotic exit when Cdk1 is inactivated by Purvalanol A, as characterized previously (S24) . In an alternative experiment, HeLa 
FIGURE S8 Inhibition by Bora on phospho-peptide-mediated activation of Plk1. (A, B)
Phospho-peptide enhances the activity of active Plx1. A phospho-peptide (P-peptide; P-M-Q-SpT-P-L) and its non-phospho version (non-P-peptide; P-M-Q-S-T-P-L) (S22) were synthesized.
It has been shown previously that P-peptide binds to the PBD and activates the Plk1 activity (S22) . Active Plx1 (80 nM) purified from okadaic acid-treated mitotic Sf9 cells was incubated with 250 μM P-peptide or non-P-peptide. The incubation mixture was then assayed for the Plx1 activity using casein as a substrate (A) and the relative kinase activity quantified and plotted (B). 
